FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3168850617> ?p ?o ?g. }

• W3168850617 endingPage "115" @default.
• W3168850617 startingPage "100" @default.
• W3168850617 abstract "Neuroendocrine carcinomas (NECs) are aggressive malignant diseases. Platinum-etoposide (PE) combination is the standard first-line treatment, whatever the primary location. The NEC score and also retinoblastoma protein (Rb) status have been suggested to be predictive/prognostic factors in NEC. The primary objective of our multicentric retrospective study was to evaluate the prognostic relevance of the NEC score and Rb status, assessed by immunohistochemistry in PE-treated patients with metastatic NEC.Seven centres participated. The inclusion criteria were NEC, whatever the primary site, metastatic stage, first-line treatment with PE and tissue samples available. Rb status was determined centrally.We report multicentric data from 185 metastatic patients (37% women, median age 63). There were 108 small-cell NECs (SCNECs, 58.4%), 50 large-cell NECs (LCNECs, 27%) and 27 not otherwise specified NECs (nosNECs, 14.6%). The primary sites were the thorax (37%), gastroenteropancreatic sites (38%), unknown (15%) and other (9%). The mean Ki-67 index was 76% (range 20-100). Rb status was interpretable in 122 cases. Rb expression was lost in 74% of the cases: 84% of SCNEC vs. 60% and 63% of LCNEC and nosNEC, respectively (p = 0.016). Objective response was seen in 70% of SCNEC, 45% of LCNEC and 48% of nosNEC (p < 0.001) and in 62% of Rb-negative tumours vs. 46% of Rb-positive tumours (p = 0.3). There was no difference in median progression-free survival or overall survival (OS) as per Rb status. Age, NEC score and response to chemotherapy were the main factors associated with OS in our cohort.In our series, Rb status had no prognostic impact in PE-treated metastatic patients with NEC, whereas age, NEC score and response to chemotherapy were the main factors associated with OS." @default.
• W3168850617 created "2021-06-22" @default.
• W3168850617 creator A5001829921 @default.
• W3168850617 creator A5007925107 @default.
• W3168850617 creator A5010577429 @default.
• W3168850617 creator A5010943886 @default.
• W3168850617 creator A5015697378 @default.
• W3168850617 creator A5016744212 @default.
• W3168850617 creator A5023803105 @default.
• W3168850617 creator A5024164679 @default.
• W3168850617 creator A5025733303 @default.
• W3168850617 creator A5028237042 @default.
• W3168850617 creator A5030440620 @default.
• W3168850617 creator A5035785078 @default.
• W3168850617 creator A5042575799 @default.
• W3168850617 creator A5045535061 @default.
• W3168850617 creator A5045804410 @default.
• W3168850617 creator A5045830986 @default.
• W3168850617 creator A5049984078 @default.
• W3168850617 creator A5051115285 @default.
• W3168850617 creator A5056390272 @default.
• W3168850617 creator A5058948162 @default.
• W3168850617 creator A5067116958 @default.
• W3168850617 creator A5072400207 @default.
• W3168850617 creator A5085121407 @default.
• W3168850617 creator A5085680950 @default.
• W3168850617 creator A5087280528 @default.
• W3168850617 date "2021-07-01" @default.
• W3168850617 modified "2023-10-17" @default.
• W3168850617 title "Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d’Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network" @default.
• W3168850617 cites W1128593298 @default.
• W3168850617 cites W1555094309 @default.
• W3168850617 cites W1903523058 @default.
• W3168850617 cites W1995681258 @default.
• W3168850617 cites W2019607817 @default.
• W3168850617 cites W2023163806 @default.
• W3168850617 cites W2023400202 @default.
• W3168850617 cites W2081457024 @default.
• W3168850617 cites W2127327720 @default.
• W3168850617 cites W2147094583 @default.
• W3168850617 cites W2155723257 @default.
• W3168850617 cites W2161676563 @default.
• W3168850617 cites W2164730570 @default.
• W3168850617 cites W2166418266 @default.
• W3168850617 cites W2170260373 @default.
• W3168850617 cites W2227093581 @default.
• W3168850617 cites W2294290225 @default.
• W3168850617 cites W2484492934 @default.
• W3168850617 cites W2581146151 @default.
• W3168850617 cites W2610009396 @default.
• W3168850617 cites W2765973383 @default.
• W3168850617 cites W2792828274 @default.
• W3168850617 cites W2793699285 @default.
• W3168850617 cites W2895496651 @default.
• W3168850617 cites W2919861477 @default.
• W3168850617 cites W3015314028 @default.
• W3168850617 cites W3126702996 @default.
• W3168850617 cites W3161225290 @default.
• W3168850617 doi "https://doi.org/10.1016/j.ejca.2021.04.030" @default.
• W3168850617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34090142" @default.
• W3168850617 hasPublicationYear "2021" @default.
• W3168850617 type Work @default.
• W3168850617 sameAs 3168850617 @default.
• W3168850617 citedByCount "7" @default.
• W3168850617 countsByYear W31688506172021 @default.
• W3168850617 countsByYear W31688506172022 @default.
• W3168850617 countsByYear W31688506172023 @default.
• W3168850617 crossrefType "journal-article" @default.
• W3168850617 hasAuthorship W3168850617A5001829921 @default.
• W3168850617 hasAuthorship W3168850617A5007925107 @default.
• W3168850617 hasAuthorship W3168850617A5010577429 @default.
• W3168850617 hasAuthorship W3168850617A5010943886 @default.
• W3168850617 hasAuthorship W3168850617A5015697378 @default.
• W3168850617 hasAuthorship W3168850617A5016744212 @default.
• W3168850617 hasAuthorship W3168850617A5023803105 @default.
• W3168850617 hasAuthorship W3168850617A5024164679 @default.
• W3168850617 hasAuthorship W3168850617A5025733303 @default.
• W3168850617 hasAuthorship W3168850617A5028237042 @default.
• W3168850617 hasAuthorship W3168850617A5030440620 @default.
• W3168850617 hasAuthorship W3168850617A5035785078 @default.
• W3168850617 hasAuthorship W3168850617A5042575799 @default.
• W3168850617 hasAuthorship W3168850617A5045535061 @default.
• W3168850617 hasAuthorship W3168850617A5045804410 @default.
• W3168850617 hasAuthorship W3168850617A5045830986 @default.
• W3168850617 hasAuthorship W3168850617A5049984078 @default.
• W3168850617 hasAuthorship W3168850617A5051115285 @default.
• W3168850617 hasAuthorship W3168850617A5056390272 @default.
• W3168850617 hasAuthorship W3168850617A5058948162 @default.
• W3168850617 hasAuthorship W3168850617A5067116958 @default.
• W3168850617 hasAuthorship W3168850617A5072400207 @default.
• W3168850617 hasAuthorship W3168850617A5085121407 @default.
• W3168850617 hasAuthorship W3168850617A5085680950 @default.
• W3168850617 hasAuthorship W3168850617A5087280528 @default.
• W3168850617 hasBestOaLocation W31688506172 @default.
• W3168850617 hasConcept C126322002 @default.
• W3168850617 hasConcept C142724271 @default.
• W3168850617 hasConcept C143998085 @default.
• W3168850617 hasConcept C146357865 @default.

• next